News & Updates

Pandemic-related delays in thrombolysis worsens outcomes
Pandemic-related delays in thrombolysis worsens outcomes
25 Apr 2022 byTristan Manalac

Patients who have had to delay their intravenous thrombolysis (IVT) procedures due to the COVID-19 pandemic suffer from worse short-term clinical outcomes such as higher rates of mortality and hospice care, reports a study presented at the Annual Meeting of the American Academy of Neurology (AAN 2022). These patients are also less likely to be discharged to their homes or to rehabilitation facilities.

Pandemic-related delays in thrombolysis worsens outcomes
25 Apr 2022
Renal denervation aids in long-term blood pressure control
Renal denervation aids in long-term blood pressure control
25 Apr 2022 byTristan Manalac

Patients with uncontrolled hypertension can benefit from renal sympathetic denervation, which leads to notable reductions in systolic blood pressure (SBP) after 6 months of intervention, reports the proof-of-concept SPYRAL HTN-ON MED trial presented at  ACC.22.

Renal denervation aids in long-term blood pressure control
25 Apr 2022
Obesity modifies link between menopausal age and heart failure risk
Obesity modifies link between menopausal age and heart failure risk
25 Apr 2022

The risk of developing heart failure appears to increase in proportion with the level of obesity, especially among women whose menopause occurred at ≥55 years of age, a study has found.

Obesity modifies link between menopausal age and heart failure risk
25 Apr 2022
Left atrial measures predict heart failure in older adults
Left atrial measures predict heart failure in older adults
24 Apr 2022
Once- on par with twice-daily cilostazol–Ginkgo biloba combo in peripheral arterial disease
Once- on par with twice-daily cilostazol–Ginkgo biloba combo in peripheral arterial disease
23 Apr 2022

In the treatment of ischemic symptoms associated with peripheral arterial disease, the use of once-daily SID142 appears to be as good as twice-daily Renexin while having a favourable safety profile, as shown in a phase III study.

Once- on par with twice-daily cilostazol–Ginkgo biloba combo in peripheral arterial disease
23 Apr 2022